Consequences of polypharmacy among the people living with dementia: a systematic review and meta-analysis
Talukdar, Imdadul Haque ; Thant, Poe Eindra and Saha, Sanjib LU
(2024)
In Aging & Mental Health
- Abstract
- Abstract
Objectives
The aim of this systematic review and meta-analysis was to analyse and summarize studies on the effects of polypharmacy on people living with dementia (PwD). The study aimed to categorize these effects, evaluate the quality of the studies, and estimate the pooled effect sizes of these consequences using meta-analysis.
Method
A systematic literature review was conducted following the PRISMA guideline. Covidence software was used for screening, study selection, and data extraction. The quality assessment was conducted using the Newcastle-Ottawa Scale (NOS) scale. Random effect models were used to perform the meta-analyses and the heterogeneity was reported with I2 statistics.
Results
This... (More) - Abstract
Objectives
The aim of this systematic review and meta-analysis was to analyse and summarize studies on the effects of polypharmacy on people living with dementia (PwD). The study aimed to categorize these effects, evaluate the quality of the studies, and estimate the pooled effect sizes of these consequences using meta-analysis.
Method
A systematic literature review was conducted following the PRISMA guideline. Covidence software was used for screening, study selection, and data extraction. The quality assessment was conducted using the Newcastle-Ottawa Scale (NOS) scale. Random effect models were used to perform the meta-analyses and the heterogeneity was reported with I2 statistics.
Results
This review of 19 studies found that polypharmacy is significantly associated with potentially inappropriate medication (PIM), hospitalisation, adverse drug reactions, and mortality. The quality of the studies was fair to good. Meta-analysis revealed that the odds of having PIM among the PwD exposed to polypharmacy was 2.93 times (95% CI: 2.24–3.82; I2 = 95.6%). The studies showed heterogeneity in design, sample size, follow-up duration, confounder adjustment, polypharmacy definitions, and inconsistent tools for dementia diagnosis.
Conclusion
Polypharmacy in PwD is associated with increased potentially inappropriate medication, adverse drug reactions, and hospitalisation. Regular management of polypharmacy is recommended in clinical practice. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/61a8a503-9d59-4d5b-a407-9d89123d5cf1
- author
- Talukdar, Imdadul Haque
; Thant, Poe Eindra
and Saha, Sanjib
LU
- organization
- publishing date
- 2024-12-09
- type
- Contribution to journal
- publication status
- epub
- subject
- in
- Aging & Mental Health
- publisher
- Taylor & Francis
- external identifiers
-
- pmid:39654286
- scopus:85211241886
- ISSN
- 1364-6915
- DOI
- 10.1080/13607863.2024.2436501
- language
- English
- LU publication?
- yes
- id
- 61a8a503-9d59-4d5b-a407-9d89123d5cf1
- date added to LUP
- 2024-12-10 08:27:46
- date last changed
- 2025-07-06 19:17:39
@article{61a8a503-9d59-4d5b-a407-9d89123d5cf1,
abstract = {{Abstract<br/>Objectives<br/>The aim of this systematic review and meta-analysis was to analyse and summarize studies on the effects of polypharmacy on people living with dementia (PwD). The study aimed to categorize these effects, evaluate the quality of the studies, and estimate the pooled effect sizes of these consequences using meta-analysis.<br/><br/>Method<br/>A systematic literature review was conducted following the PRISMA guideline. Covidence software was used for screening, study selection, and data extraction. The quality assessment was conducted using the Newcastle-Ottawa Scale (NOS) scale. Random effect models were used to perform the meta-analyses and the heterogeneity was reported with I2 statistics.<br/><br/>Results<br/>This review of 19 studies found that polypharmacy is significantly associated with potentially inappropriate medication (PIM), hospitalisation, adverse drug reactions, and mortality. The quality of the studies was fair to good. Meta-analysis revealed that the odds of having PIM among the PwD exposed to polypharmacy was 2.93 times (95% CI: 2.24–3.82; I2 = 95.6%). The studies showed heterogeneity in design, sample size, follow-up duration, confounder adjustment, polypharmacy definitions, and inconsistent tools for dementia diagnosis.<br/><br/>Conclusion<br/>Polypharmacy in PwD is associated with increased potentially inappropriate medication, adverse drug reactions, and hospitalisation. Regular management of polypharmacy is recommended in clinical practice.}},
author = {{Talukdar, Imdadul Haque and Thant, Poe Eindra and Saha, Sanjib}},
issn = {{1364-6915}},
language = {{eng}},
month = {{12}},
publisher = {{Taylor & Francis}},
series = {{Aging & Mental Health}},
title = {{Consequences of polypharmacy among the people living with dementia: a systematic review and meta-analysis}},
url = {{http://dx.doi.org/10.1080/13607863.2024.2436501}},
doi = {{10.1080/13607863.2024.2436501}},
year = {{2024}},
}